The microRNA member miR-204-5p inhibits apoptosis in melanoma cells treated with dacarbazine or when overexpressed.
2023
Study identifies key regulator of melanoma development
Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.
Development of FHD-286 Monotherapy Will Not Continue in Metastatic Uveal Melanoma
Although the highly potent, selective, allosteric, oral, small molecule BRG1/BRM inhibitor FHD-286 elicited signs of clinical activity and safety as monotherapy in patients with metastatic uveal melanoma in the dose-escalation portion of a phase 1 trial (NCT04879017), further development in this indication will not be pursued, according to an announcement from Foghorn Therapeutics.
Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma
Pembrolizumab (Keytruda) led to sustained improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma, according to updated data from the phase 3 KEYNOTE-716 trial (NCT03553836) presented at the 2023 ASCO Annual Meeting.